Observational Study to Evaluate Fertility in Women Between 32 and 38 Years Old Treated With the Ovosicare® Fertility
NCT ID: NCT07083999
Last Updated: 2025-07-24
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
300 participants
OBSERVATIONAL
2025-02-13
2026-12-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Antioxidants vs. Ovarian Bio-stimulation Therapy to Rescue the Ovarian Reserve
NCT03621683
Ovarian PRP (Platelet Rich Plasma) Injection for Follicular Activation
NCT05279560
Effects of Intraovarian Platelet Rich Plasma in Women With Poor Ovarian Response and Premature Ovarian Insufficiency
NCT04237909
Autologous Platelet-Rich Plasma Intra-ovarian Infusion in Poor Responders
NCT03937661
Autologous Intraovarian Platelet Rich Plasma Treatment in Women With Poor Ovarian Response
NCT04797377
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
The number of visits throughout the study will be a total of three. Please note that you will not have to undergo additional tests or attend any extraordinary visits due to participating in this study, since the procedures you will undergo are the same as those routinely carried out in clinical practice.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_ONLY
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Suplementation
Women on Ovosicare Fertility supplementation prescribed according to standard clinical practice
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. \- Between 32 and 38 years old.
3. \- Who come to doctor´s office stating that they have been trying to get pregnant for at least 6 months.
Exclusion Criteria
2. \- Existence of severe male factor subfertility according to the criteria of the World Health Organization (WHO), with at least one analysis obtained in the last 6 months with one or more variables with values of:
* Azoospermia
* Progressive motility \<25%
* Normal morphology ≤2%
3. \- Pregnant or breastfeeding women.
4. \- Patients with type 1 diabetes or thyroid disease.
5. \- Patients with any assisted reproduction technique scheduled during the duration of the study.
6. \- Patients who have used or taken systemic steroids, anticonvulsants, antiretroviral treatment for HIV or hepatitis B in the last month.
7. \- Patients with a known allergy to any of the components of Ovosicare® Fertility.
8. \- Any other situation that, in the medical opinion, advises against treatment with Ovosicare® Fertility or that may make patient follow-up difficult.
9. \- Patients with suspected endometriosis.
10. \- Existence of fibroids affecting the endometrial cavity.
11. \- Patients with 2 or more previous abortions.
12. \- Patients with a current diagnosis of a high-risk human papillomavirus (HPV) cervical lesion.
32 Years
38 Years
FEMALE
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Procare Health Iberia S.L.
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
CM Sitges
Sitges, Barcelona, Spain
HU de Getafe
Getafe, Madrid, Spain
Clínica Rv Benalmádena
Benalmádena, Malaga, Spain
H García Orcoyen
Estella-Lizarra, Navarre, Spain
CP Dr. Andrade Andrade
A Coruña, , Spain
CP Dra. Domenech Casanova
Alicante, , Spain
H Vega Baja de Orihuela
Alicante, , Spain
Clinica Alboran
Almería, , Spain
CP Dr. Aragón Albillos
Almería, , Spain
CM Teknon
Barcelona, , Spain
CP Dra. Mallafre
Barcelona, , Spain
HU Vall d'Hebron
Barcelona, , Spain
OBS Ginecólogos Burgos
Burgos, , Spain
Clínica Attella
Castelló, , Spain
HU de Donostia
Donostia / San Sebastian, , Spain
CP Dra. Skouri-Bnihech Tioua
Granada, , Spain
CHU Insular - H Materno-Infantil
Las Palmas, , Spain
Clínica Palacios
Madrid, , Spain
Gymeiaka Dra. Oltra Badui
Madrid, , Spain
Gymeiaka Dra. Pavón Sanz
Madrid, , Spain
HU La Paz
Madrid, , Spain
Clínica Imar
Murcia, , Spain
Ancla Clínica Ginecológica
Pontevedra, , Spain
HG de la Santísima Trinidad
Salamanca, , Spain
CP Dra. Sánchez Quintana
Seville, , Spain
HU i Politècnic la Fe
Valencia, , Spain
Centro Ginecológico Bolonia
Zaragoza, , Spain
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
FERTILOBS
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.